nuclear factor kappa B

nuclear factor kappa B
Name	NF-κB

nuclear factor kappa B

Nuclear factor kappa B is a conserved transcription factor complex central to transcriptional responses in many eukaryotic cells. It integrates signals from receptors and intracellular stress sensors to control genes involved in immunity, inflammation, cell survival, and development. Discovered through studies of immunoglobulin light-chain enhancers and viral oncogenesis, the factor links pathways studied by laboratories associated with figures such as David Baltimore, Philipp M. Huber, and institutions like the National Institutes of Health and Max Planck Society.

Introduction

NF-κB was first characterized in work that connected enhancer binding in B cells with viral activation, placing it alongside concepts explored by Howard Temin and Rita Levi-Montalcini in cellular control. The canonical complex name refers to kappa light chains originally studied in experiments at institutions such as Columbia University and University of California, San Francisco. Subsequent structural and biochemical characterization involved collaborations with research groups at Harvard University, Cold Spring Harbor Laboratory, and Rockefeller University. NF-κB signaling intersects pathways investigated by researchers affiliated with Yale University, Stanford University, and the Max Planck Institute for Biochemistry.

Structure and family members

The NF-κB family comprises Rel homology domain-containing proteins first related to work from laboratories like Yasuke Ishihama and Günter Blobel. Family members include RelA (p65), RelB, c-Rel, p50 (processed from p105), and p52 (processed from p100). Structural studies conducted in collaborations between teams at European Molecular Biology Laboratory, Massachusetts Institute of Technology, and University of Cambridge revealed DNA-binding and dimerization interfaces analogous to domains characterized by Ada Yonath and Thomas A. Steitz. The Rel homology domain mediates interactions also studied in the context of transcription factors examined by Eric Lander and James Watson. Post-translational modification sites such as phosphorylation and ubiquitination were mapped using techniques developed at Scripps Research and Karolinska Institutet.

Activation pathways

Activation proceeds via canonical and non-canonical pathways mapped by groups at Johns Hopkins University and University of Oxford. The canonical pathway is initiated by receptors including Tumor necrosis factor receptor family members and Toll-like receptors studied by researchers like Bruce Beutler and Jules A. Hoffman, leading to IκB kinase (IKK) complex activation; the IKK complex components IKKα, IKKβ, and NEMO (IKKγ) were characterized in labs at University of Pennsylvania and Institut Pasteur. The non-canonical pathway requires NF-κB–inducing kinase (NIK) and processes p100 to p52; this branch was elucidated with contributions from investigators at Columbia University and University College London. Viral proteins from Epstein–Barr virus and Human immunodeficiency virus are known to hijack these pathways, as shown in studies at National Cancer Institute and Fred Hutchinson Cancer Research Center.

Biological functions

NF-κB regulates genes controlling cytokines such as those studied in work on Interleukin-6, Tumor necrosis factor, and Interleukin-1, and chemokines characterized in research at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. It modulates apoptosis-related genes examined by groups at Cold Spring Harbor Laboratory and Salk Institute for Biological Studies. In development, NF-κB roles overlap with signaling axes studied by scientists at California Institute of Technology and Princeton University. Immune system regulation involving dendritic cells and lymphocytes links NF-κB to discoveries from Rockefeller University and Imperial College London. Metabolic and stress responses tied to NF-κB have been probed in studies at University of Chicago and Karolinska Institutet.

Regulation and inhibitors

NF-κB is regulated by inhibitory IκB proteins (IκBα, IκBβ, IκBε) described in biochemical work from Harvard Medical School and University of Basel. Ubiquitin-editing enzymes such as A20 and CYLD, characterized at Weizmann Institute of Science and University of Texas Southwestern Medical Center, control pathway termination. Small-molecule IKK inhibitors were developed through medicinal chemistry efforts involving collaborations with GlaxoSmithKline, Novartis, and academic screening centers at European Molecular Biology Laboratory. Endogenous negative regulators and feedback loops were mapped by researchers at University of Pennsylvania and Yale School of Medicine.

Role in disease

Dysregulated NF-κB signaling contributes to inflammatory diseases and cancers studied at centers including Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic. Constitutive activation is observed in lymphomas and leukemias characterized by groups at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Chronic inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease have NF-κB signatures identified in clinical studies from Mayo Clinic and Mount Sinai Health System. Viral oncogenesis involving Human T-lymphotropic virus and Epstein–Barr virus links NF-κB to malignancies investigated at National Institutes of Health and Fred Hutchinson Cancer Research Center.

Therapeutic targeting and clinical relevance

Therapeutic strategies targeting NF-κB include small-molecule inhibitors, proteasome inhibitors such as those developed by F. Hoffmann-La Roche, and biologics targeting upstream cytokines pioneered by companies like AbbVie and Johnson & Johnson. Clinical trials testing IKK inhibitors and pathway modulators have been conducted in networks including National Cancer Institute cooperative groups and pharmaceutical consortia involving Pfizer and Merck & Co.. Biomarker work linking NF-κB activity to prognosis and treatment response has been advanced at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Continued translational efforts bridge basic research from institutions like Stanford University and University of California, San Diego with clinical applications in oncology, immunology, and chronic disease management.

Category:Transcription factors